Literature DB >> 7857146

Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma.

S Singer1, J M Corson, G D Demetri, E A Healey, K Marcus, T J Eberlein.   

Abstract

OBJECTIVE: The authors identified prognostic factors relevant to clinical outcomes (especially survival) in truncal and retroperitoneal soft-tissue sarcoma. SUMMARY BACKGROUND DATA: These results can be used to optimize surgical management and select patients most likely to benefit from novel therapeutic strategies in future trials.
METHODS: A retrospective analysis was performed of a prospectively compiled database of 183 consecutive patients with truncal and retroperitoneal sarcomas seen at the Brigham and Women's Hospital and the Dana Farber Cancer Institute between 1970 to 1994.
RESULTS: For truncal sarcoma, multivariate analysis showed that high-grade histology was associated with an eightfold increased risk of death compared with low-grade histology (p = 0.001). In addition to grade, gross positive margin of resection (p = 0.001), microscopic positive margin (p = 0.023), and tumors greater than 5 cm in size (p = 0.018) were important independent prognostic factors for survival. In this series, postoperative radiation therapy for truncal sarcoma was associated with a 2.4-fold decreased risk of death compared with truncal sarcoma patients receiving no adjuvant radiation therapy, having adjusted for the other prognostic factors (p = 0.030). In contrast, for retroperitoneal sarcoma, multivariate analysis showed that high-grade and intermediate-grade histology were associated with a five- to sixfold increased risk of death compared with low-grade histology (p = 0.009). In addition to grade, gross positive margin of resection (p = 0.001) and microscopic positive margin (p = 0.004) were important independent prognostic factors for survival in retroperitoneal sarcoma. Patients who received either preoperative or postoperative chemotherapy for retroperitoneal sarcoma had a 4.6-fold (p = 0.002) and 3-fold (p = 0.010) increased risk of death, respectively, compared with patients receiving no adjuvant chemotherapy, having adjusted for the other prognostic factors.
CONCLUSIONS: The histologic grade and the margin of resection are prognostic for survival in both truncal and retroperitoneal soft-tissue sarcoma. Tumor size was an independent prognostic factor for truncal sarcoma, but not for retroperitoneal sarcoma. Postoperative adjuvant radiation was beneficial to overall survival for truncal sarcoma. In this series of patients receiving a heterogeneous mixture of chemotherapeutic regimens-either as preoperative "neoadjuvant" therapy or as postoperative "adjuvant" therapy, there were no beneficial effects on survival compared with nonrandomized patients not receiving chemotherapy.

Entities:  

Mesh:

Year:  1995        PMID: 7857146      PMCID: PMC1234952          DOI: 10.1097/00000658-199502000-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  16 in total

1.  Prognostic factors in primary retroperitoneal soft-tissue sarcomas.

Authors:  R G Bevilacqua; A Rogatko; S I Hajdu; M F Brennan
Journal:  Arch Surg       Date:  1991-03

2.  Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma.

Authors:  S Singer; J M Corson; R Gonin; B Labow; T J Eberlein
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

3.  Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group.

Authors:  T A Alvegård; H Sigurdsson; H Mouridsen; O Solheim; B Unsgaard; U Ringborg; O Dahl; A M Nordentoft; C Blomqvist; A Rydholm
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

4.  Local recurrence in adult soft-tissue sarcoma. A randomized trial of brachytherapy.

Authors:  M F Brennan; B Hilaris; M H Shiu; J Lane; G Magill; C Friedrich; S I Hajdu
Journal:  Arch Surg       Date:  1987-11

5.  Treatment of extremity soft tissue sarcomas with surgery and radiotherapy.

Authors:  M Robinson; L Barr; C Fisher; I Fryatt; A Stotter; C Harmer; E Wiltshaw; G Westbury
Journal:  Radiother Oncol       Date:  1990-07       Impact factor: 6.280

6.  Postoperative radiotherapy in the treatment of extremity soft tissue sarcomas.

Authors:  W J Pao; M V Pilepich
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-10       Impact factor: 7.038

7.  Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment.

Authors:  H D Suit; W O Russell; R G Martin
Journal:  Cancer       Date:  1975-05       Impact factor: 6.860

8.  Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups.

Authors:  K Antman; H Suit; D Amato; J Corson; W Wood; K Proppe; D Harmon; R Carey; J Greenberger; R Blum
Journal:  J Clin Oncol       Date:  1984-06       Impact factor: 44.544

9.  Localized extremity soft tissue sarcoma: an analysis of factors affecting survival.

Authors:  C Collin; J Godbold; S Hajdu; M Brennan
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

10.  The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.

Authors:  S A Rosenberg; J Tepper; E Glatstein; J Costa; A Baker; M Brennan; E V DeMoss; C Seipp; W F Sindelar; P Sugarbaker; R Wesley
Journal:  Ann Surg       Date:  1982-09       Impact factor: 12.969

View more
  64 in total

Review 1.  Soft tissue sarcomas and p53 mutations.

Authors:  H Taubert; A Meye; P Würl
Journal:  Mol Med       Date:  1998-06       Impact factor: 6.354

2.  Long-term results of primary and secondary resections in patients with retroperitoneal soft tissue sarcoma.

Authors:  Alexandra M Koenig; Matthias Reeh; Christoph M Burdelski; Claudia Wengert; Karim A Gawad; Jakob R Izbicki; Maximilian Bockhorn
Journal:  Langenbecks Arch Surg       Date:  2012-03-10       Impact factor: 3.445

3.  Tumeurs rétropéritonéales primitives : Profils diagnostique, thérapeutique et anatomopathologique.

Authors:  Adil Aitsakel; Hachem Elsayegh; Lounis Benslimane; Yassine Nouini
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

4.  [Retroperitoneal leiomyosarcoma. A rare differential diagnosis of an adrenal tumor].

Authors:  J Hodzic; K Golka; K Möhring; G Riedasch
Journal:  Urologe A       Date:  2006-02       Impact factor: 0.639

5.  Retroperitoneal sarcomas- a challenging problem.

Authors:  Vijay Kumar; Sanjeev Misra; Arun Chaturvedi
Journal:  Indian J Surg Oncol       Date:  2012-05-30

6.  Resection of the Inferior Vena Cava for Retroperitoneal Sarcoma: Six Cases and a Review of Literature.

Authors:  Joy Ghose; Rahul Bhamre; Nikhil Mehta; Ashwin Desouza; Shraddha Patkar; Jayesh Dhareshwar; Mahesh Goel; Shailesh V Shrikhande
Journal:  Indian J Surg Oncol       Date:  2018-07-19

7.  Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy.

Authors:  Paul Nikolaidis; Stuart G Silverman; Edmund S Cibas; Eric Vansonnenberg; Frank J Rybicki; Judith B Manola; Kemal Tuncali; Steven H Karshbaum; Samuel Singer; Christopher D M Fletcher; George D Demetri
Journal:  Eur Radiol       Date:  2004-10-06       Impact factor: 5.315

Review 8.  A guide to oncological management of soft tissue tumours of the abdominal wall.

Authors:  K J Williams; A J Hayes
Journal:  Hernia       Date:  2013-09-17       Impact factor: 4.739

9.  Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule.

Authors:  James O Park; Li-Xuan Qin; Francesco P Prete; Cristina Antonescu; Murray F Brennan; Samuel Singer
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

10.  Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region.

Authors:  Antoine Lurkin; Francoise Ducimetière; Dominique Ranchère Vince; Anne-Valérie Decouvelaere; Dominic Cellier; François N Gilly; Dimitri Salameire; Pierre Biron; Guy de Laroche; Jean Yves Blay; Isabelle Ray-Coquard
Journal:  BMC Cancer       Date:  2010-04-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.